The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial
Purpose To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC). Materials and Methods Eighteen patients with HRPC were recruited for this phase II trial in which they received...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2004-09, Vol.60 (4), p.332-337 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 337 |
|---|---|
| container_issue | 4 |
| container_start_page | 332 |
| container_title | The Prostate |
| container_volume | 60 |
| creator | Ziada, Ali Barqawi, Albaha Glode, L. Michael Varella-Garcia, Marileila Crighton, Frances Majeski, Susan Rosenblum, Mark Kane, Madeleine Chen, Lin Crawford, E. David |
| description | Purpose
To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC).
Materials and Methods
Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER‐2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual‐color fluorescence in‐situ hybridization (FISH) assays.
Results
Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications.
Conclusions
Trastuzumab (Herceptin®) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin® and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC. © 2004 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pros.20065 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pros_20065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_9H7WP059_0</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4585-90db6e16763cbddac59be6ae17ad4d0dced682dde650677eb2ed03ecad25cf3f3</originalsourceid><addsrcrecordid>eNp9kEFPAjEUhBujEUQv_gDTs8nia3fbsvFkjAIJEaIYTqbptm_DKsuSbonir3cR1Jund5hv5k2GkHMGXQbAr1a-qrscQIoD0maQqgggEYekDVxBlLBYtchJXb8CNDjwY9JigsuEJ6JNXqZzpOsaaZXT4E0d1p_r0mS0WNLQKMGjCSUuw1afV76slkg95t7YUPkN3b4OJiC1ZmnRX9PV3DRhw2HjLMzilBzlZlHj2f52yPP93fR2EI3G_eHtzSiyieiJKAWXSWRSydhmzhkr0gylQaaMSxw4i072uHMoBUilMOPoIEZrHBc2j_O4Qy53ubbpUzf99MoXpfEbzUBvN9Lbovp7owa-2MGrdVai-0P3ozQA2wHvxQI3_0TpyeP46Sc02nmKOuDHr8f4Ny1VrISePfR1OlCzCYhUQ_wFjquDMg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ziada, Ali ; Barqawi, Albaha ; Glode, L. Michael ; Varella-Garcia, Marileila ; Crighton, Frances ; Majeski, Susan ; Rosenblum, Mark ; Kane, Madeleine ; Chen, Lin ; Crawford, E. David</creator><creatorcontrib>Ziada, Ali ; Barqawi, Albaha ; Glode, L. Michael ; Varella-Garcia, Marileila ; Crighton, Frances ; Majeski, Susan ; Rosenblum, Mark ; Kane, Madeleine ; Chen, Lin ; Crawford, E. David</creatorcontrib><description>Purpose
To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC).
Materials and Methods
Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER‐2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual‐color fluorescence in‐situ hybridization (FISH) assays.
Results
Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications.
Conclusions
Trastuzumab (Herceptin®) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin® and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC. © 2004 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.20065</identifier><identifier>PMID: 15264245</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; cancer ; Carcinoma - drug therapy ; Carcinoma - pathology ; Disease Progression ; Drug Resistance, Neoplasm ; HER-2 receptor ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Infusions, Intravenous ; Male ; Middle Aged ; prostate ; Prostate-Specific Antigen - analysis ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; Receptor, ErbB-2 - biosynthesis ; Trastuzumab ; Treatment Outcome</subject><ispartof>The Prostate, 2004-09, Vol.60 (4), p.332-337</ispartof><rights>Copyright © 2004 Wiley‐Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4585-90db6e16763cbddac59be6ae17ad4d0dced682dde650677eb2ed03ecad25cf3f3</citedby><cites>FETCH-LOGICAL-c4585-90db6e16763cbddac59be6ae17ad4d0dced682dde650677eb2ed03ecad25cf3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.20065$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.20065$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15264245$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ziada, Ali</creatorcontrib><creatorcontrib>Barqawi, Albaha</creatorcontrib><creatorcontrib>Glode, L. Michael</creatorcontrib><creatorcontrib>Varella-Garcia, Marileila</creatorcontrib><creatorcontrib>Crighton, Frances</creatorcontrib><creatorcontrib>Majeski, Susan</creatorcontrib><creatorcontrib>Rosenblum, Mark</creatorcontrib><creatorcontrib>Kane, Madeleine</creatorcontrib><creatorcontrib>Chen, Lin</creatorcontrib><creatorcontrib>Crawford, E. David</creatorcontrib><title>The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>Purpose
To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC).
Materials and Methods
Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER‐2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual‐color fluorescence in‐situ hybridization (FISH) assays.
Results
Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications.
Conclusions
Trastuzumab (Herceptin®) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin® and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC. © 2004 Wiley‐Liss, Inc.</description><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>cancer</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - pathology</subject><subject>Disease Progression</subject><subject>Drug Resistance, Neoplasm</subject><subject>HER-2 receptor</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>prostate</subject><subject>Prostate-Specific Antigen - analysis</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>Trastuzumab</subject><subject>Treatment Outcome</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFPAjEUhBujEUQv_gDTs8nia3fbsvFkjAIJEaIYTqbptm_DKsuSbonir3cR1Jund5hv5k2GkHMGXQbAr1a-qrscQIoD0maQqgggEYekDVxBlLBYtchJXb8CNDjwY9JigsuEJ6JNXqZzpOsaaZXT4E0d1p_r0mS0WNLQKMGjCSUuw1afV76slkg95t7YUPkN3b4OJiC1ZmnRX9PV3DRhw2HjLMzilBzlZlHj2f52yPP93fR2EI3G_eHtzSiyieiJKAWXSWRSydhmzhkr0gylQaaMSxw4i072uHMoBUilMOPoIEZrHBc2j_O4Qy53ubbpUzf99MoXpfEbzUBvN9Lbovp7owa-2MGrdVai-0P3ozQA2wHvxQI3_0TpyeP46Sc02nmKOuDHr8f4Ny1VrISePfR1OlCzCYhUQ_wFjquDMg</recordid><startdate>20040901</startdate><enddate>20040901</enddate><creator>Ziada, Ali</creator><creator>Barqawi, Albaha</creator><creator>Glode, L. Michael</creator><creator>Varella-Garcia, Marileila</creator><creator>Crighton, Frances</creator><creator>Majeski, Susan</creator><creator>Rosenblum, Mark</creator><creator>Kane, Madeleine</creator><creator>Chen, Lin</creator><creator>Crawford, E. David</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20040901</creationdate><title>The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial</title><author>Ziada, Ali ; Barqawi, Albaha ; Glode, L. Michael ; Varella-Garcia, Marileila ; Crighton, Frances ; Majeski, Susan ; Rosenblum, Mark ; Kane, Madeleine ; Chen, Lin ; Crawford, E. David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4585-90db6e16763cbddac59be6ae17ad4d0dced682dde650677eb2ed03ecad25cf3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>cancer</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - pathology</topic><topic>Disease Progression</topic><topic>Drug Resistance, Neoplasm</topic><topic>HER-2 receptor</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>prostate</topic><topic>Prostate-Specific Antigen - analysis</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>Trastuzumab</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ziada, Ali</creatorcontrib><creatorcontrib>Barqawi, Albaha</creatorcontrib><creatorcontrib>Glode, L. Michael</creatorcontrib><creatorcontrib>Varella-Garcia, Marileila</creatorcontrib><creatorcontrib>Crighton, Frances</creatorcontrib><creatorcontrib>Majeski, Susan</creatorcontrib><creatorcontrib>Rosenblum, Mark</creatorcontrib><creatorcontrib>Kane, Madeleine</creatorcontrib><creatorcontrib>Chen, Lin</creatorcontrib><creatorcontrib>Crawford, E. David</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ziada, Ali</au><au>Barqawi, Albaha</au><au>Glode, L. Michael</au><au>Varella-Garcia, Marileila</au><au>Crighton, Frances</au><au>Majeski, Susan</au><au>Rosenblum, Mark</au><au>Kane, Madeleine</au><au>Chen, Lin</au><au>Crawford, E. David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2004-09-01</date><risdate>2004</risdate><volume>60</volume><issue>4</issue><spage>332</spage><epage>337</epage><pages>332-337</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><abstract>Purpose
To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC).
Materials and Methods
Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER‐2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual‐color fluorescence in‐situ hybridization (FISH) assays.
Results
Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications.
Conclusions
Trastuzumab (Herceptin®) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin® and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC. © 2004 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15264245</pmid><doi>10.1002/pros.20065</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2004-09, Vol.60 (4), p.332-337 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_pros_20065 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use cancer Carcinoma - drug therapy Carcinoma - pathology Disease Progression Drug Resistance, Neoplasm HER-2 receptor Humans Immunohistochemistry In Situ Hybridization, Fluorescence Infusions, Intravenous Male Middle Aged prostate Prostate-Specific Antigen - analysis Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Receptor, ErbB-2 - biosynthesis Trastuzumab Treatment Outcome |
| title | The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A28%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20use%20of%20trastuzumab%20in%20the%20treatment%20of%20hormone%20refractory%20prostate%20cancer;%20phase%20II%20trial&rft.jtitle=The%20Prostate&rft.au=Ziada,%20Ali&rft.date=2004-09-01&rft.volume=60&rft.issue=4&rft.spage=332&rft.epage=337&rft.pages=332-337&rft.issn=0270-4137&rft.eissn=1097-0045&rft_id=info:doi/10.1002/pros.20065&rft_dat=%3Cistex_cross%3Eark_67375_WNG_9H7WP059_0%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15264245&rfr_iscdi=true |